Cancer
Hepatocellular carcinoma
肝细胞癌HCC
A primary cancer of the liver's main cells (hepatocytes). Tumours range from well differentiated, with cells that look like normal liver cells, to poorly differentiated.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 194
- cities
- 62
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 53% of the world's English-language research papers on hepatocellular carcinoma, 2021–2025 (41% in 2016–2020), and 36% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
194 hospitals in 62 cities
Order: papers led on hepatocellular carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 16 papers or 1 trial on hepatocellular carcinoma, or was a site in 8 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens hepatocellular carcinoma in that city. 52 more cities are in the menu below.
- 408 papers led
- 392 papers led
- 281 papers led
- 258 papers led
- 238 papers led
- 219 papers led
- 214 papers led
- 184 papers led
- 171 papers led
- 169 papers led
- 149 papers led
- 145 papers ledNo open trial led
- 144 papers led
- 135 papers ledNo open trial led
- 127 papers led
- 122 papers led
- 119 papers led
- 119 papers ledNo open trial led
- 117 papers led
- 108 papers ledNo open trial led
- 104 papers led
- 103 papers led
- 101 papers ledNo open trial led
- 97 papers ledNo open trial led
- 97 papers ledNo open trial led
- 96 papers led
- 96 papers ledNo open trial led
- 95 papers led
- 91 papers led
- 88 papers led
- 87 papers ledNo open trial led
- 84 papers led
- 83 papers led
- 80 papers led
- 76 papers led
- 76 papers ledNo open trial led
- 73 papers ledNo open trial led
- 72 papers ledNo open trial led
- 70 papers ledNo open trial led
- 68 papers led
- 67 papers ledNo open trial led
- 67 papers ledNo open trial led
- 66 papers led
- 66 papers led
- 65 papers led
- 64 papers led
- 63 papers ledNo open trial led
- 62 papers led
- 61 papers led
- 60 papers led
- 59 papers ledNo open trial led
- 59 papers led
- 59 papers led
- 58 papers ledNo open trial led
- 58 papers ledNo open trial led
- 57 papers ledNo open trial led
- 57 papers ledNo open trial led
- 55 papers ledNo open trial led
- 54 papers led
- 54 papers ledNo open trial led
- 54 papers led
- 54 papers led
- 51 papers led
- 51 papers ledNo open trial led
- 50 papers ledNo open trial led
- 49 papers ledNo open trial led
- 47 papers ledNo open trial led
- 46 papers ledNo open trial led
- 45 papers led
- 45 papers ledNo open trial led
- 45 papers ledNo open trial led
- 43 papers led
- 42 papers led
- 42 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 40 papers ledNo open trial led
- 39 papers led
- 38 papers ledNo open trial led
- 36 papers ledNo open trial led
- 36 papers led
- 36 papers ledNo open trial led
- 35 papers ledNo open trial led
- 35 papers ledNo open trial led
- 35 papers led
- 35 papers led
- 35 papers led
- 34 papers led
- 33 papers led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 28 papers ledNo open trial led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 27 papers ledNo open trial led
- 25 papers led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 24 papers ledNo open trial led
- 24 papers led
- 24 papers led
- 23 papers ledNo open trial led
- 23 papers led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 21 papers led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers led
- 21 papers ledNo open trial led
- 20 papers led
- 20 papers led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers led
- 19 papers led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers led
- 15 papers led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 12 papers led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers led
- 9 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 4 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 1 paper led
- 1 paper ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 59
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 820 papers led6 hospitals
- 603 papers led6 hospitals
- 520 papers led6 hospitals
- 414 papers led5 hospitals
- 413 papers led6 hospitals
- 378 papers led6 hospitals
- 301 papers led6 hospitals
- 290 papers led6 hospitals
- 288 papers led6 hospitals
- 284 papers led6 hospitals
- 260 papers led6 hospitals
- 250 papers led6 hospitals
- 246 papers led6 hospitals
- 239 papers led6 hospitals
- 233 papers led5 hospitals
- 224 papers led6 hospitals
- 219 papers led6 hospitals
- 194 papers led4 hospitals
- 193 papers led6 hospitals
- 191 papers led6 hospitals
- 184 papers led6 hospitals
- 184 papers led1 hospital
- 181 papers led6 hospitals
- 165 papers led6 hospitals
- 157 papers led6 hospitals
- 153 papers led6 hospitals
- 151 papers led6 hospitals
- 148 papers led6 hospitals
- 145 papers led1 hospital
- 137 papers led5 hospitals
- 135 papers led5 hospitals
- 135 papers led6 hospitals
- 125 papers led6 hospitals
- 108 papers led1 hospital
- 107 papers led6 hospitals
- 107 papers led5 hospitals
- 105 papers led4 hospitals
- 102 papers led6 hospitals
- 99 papers led6 hospitals
- 97 papers led1 hospital
- 84 papers led6 hospitals
- 82 papers led6 hospitals
- 76 papers led6 hospitals
- 74 papers led6 hospitals
- 73 papers led6 hospitals
- 71 papers led6 hospitals
- 67 papers led3 hospitals
- 66 papers led1 hospital
- 60 papers led5 hospitals
- 42 papers led5 hospitals
- 41 papers led1 hospital
- 40 papers led6 hospitals
- 37 papers led6 hospitals
- 36 papers led2 hospitals
- 35 papers led1 hospital
- 31 papers led1 hospital
- 31 papers led4 hospitals
- 25 papers led1 hospital
- 16 papers led1 hospital
open trials on hepatocellular carcinoma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 286 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingEfficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT06794073
Age 18 years to 80 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07070076
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Jinan UniversityGuangzhou
- RecruitingNIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07295262
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07295275
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 2 listed hospitals as study sitesBeijing, Chengdu, Xuzhou
- RecruitingDiagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07295340
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPhase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07310173
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingSintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07324824
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328009
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingA Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07351669
Age 18 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07381634
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingSBRT Versus Surgical Resection for Small HCC
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07381660
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07410715
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07413354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingAdjuvant TACE in HCC With High-risk Recurrence Factors
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07417397
Age 18 years to 70 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingA Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07422753
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07463248
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07475026
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07478302
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning
- RecruitingMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07479485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Registry
- NCT07482059
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07483359
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingTACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07487662
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07490262
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAn Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07493044
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingIntelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07495735
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07500220
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingEfficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07501351
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07521852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai
- RecruitingBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07523529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingBecotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07536789
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07538882
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingIpilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07560488
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07589244
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Recruiting68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07590336
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingHAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07594340
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingLenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07639138
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07658833
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingGPC3-Targeted PET/CT in Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07677774
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07776080
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07793695
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingGPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07795437
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingIRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07799922
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingIparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07801287
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEffect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07811687
Age 18 years to 80 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingBiomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07840092
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07848750
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-01
- Registry
- NCT06676982
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingHAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06737913
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou
- RecruitingHepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06741020
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06742892
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingClinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06762782
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingStereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06766643
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingCamrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- Phase
- Phase 2/Phase 3
- Started
- 2025-02
- Registry
- NCT06796803
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai
- RecruitingHAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06812039
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin
- RecruitingContinuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06841172
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06844357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingHAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06860490
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingExploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06861114
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingPhase I Study of OriC902 in Treatment of Advanced HCC
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06891742
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06893887
Age 18 years to Not stated (registered criteria)
Led by Nanjing Tianyinshan HospitalNanjing
- RecruitingTACE Combined Surgery for the Resectable Huge HCC
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06898398
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06902389
Age 18 years to 75 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- RecruitingLenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904183
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06904196
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSIRT Versus cTACE for Unresectable HCC (CHANCE2506)
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06909708
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Registry
- NCT06938880
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingReal-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06940102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingTextbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06950827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingIparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT06954116
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingFGF19 Overexpression Combination Unified Study in HCC-19
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06978933
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT06986785
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPersonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT06995105
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingHead-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07010198
Age 35 years to Not stated (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingFOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07012798
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07014150
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingPIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07018518
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07039201
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07047586
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07052253
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingPD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07053072
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPredicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07059936
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingBITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07062055
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingAI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07062380
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingApplication of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07077356
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingReal-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07079150
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingLparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07099274
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07100392
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingTACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100405
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07106827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingAutologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07123545
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07141056
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang
- RecruitingDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07147101
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingThe Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07147335
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, University of South ChinaHengyang
- RecruitingThe Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07150624
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingApatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07154082
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07157969
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingRadiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT07179900
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingSystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07192185
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingGKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07209813
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou
- RecruitingSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07227012
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingDeep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07235410
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingDalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07238881
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07239245
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou
- RecruitingTC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07242417
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingStudy on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07243691
Age 18 years to Not stated (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingA Study of DEG6498 in Participants With Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07244835
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingCamrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07267806
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07268131
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingJMT106 Injection in the Treatment of Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07275073
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingMultimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Registry
- NCT07282184
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Registry
- NCT07285850
Age 18 years to Not stated (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- Recruitingβ-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07317414
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou
- RecruitingDEB-TACE vs cTACE in HCC After TIPS
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07322848
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingNWRD06 DNA Plasmid for HCC After Curative Resection.
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07324304
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07327788
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingSintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07331883
Age 18 years to 75 years (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- RecruitingEfcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07337421
Age 18 years to 75 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingEfficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07337460
Age 18 years to 75 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07359586
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07376707
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07391839
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou
- RecruitingConstruction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07417800
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingImpact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07436845
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingcfDNA Methylation for Liver Cancer Recurrence Detection
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07466602
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT07495215
Age 18 years to 75 years (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingPeg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07769827
Age 18 years to Not stated (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingAnlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07806292
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingIrreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07832006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingCadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06215651
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingImmunotherapy for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06241326
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingHAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06244225
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingCryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06265350
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06280105
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingImpact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06280313
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingRituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06301399
Age 17 years to 79 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06307925
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPhase 2 Study of WGI-0301 for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06309485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
- RecruitingPrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Phase
- Phase 4
- Started
- 2024-04
- Registry
- NCT06311929
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCombination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06313190
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06349317
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06349980
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Phase
- Phase 4
- Started
- 2024-10
- Registry
- NCT06353126
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06360042
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingCombination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06363006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06371157
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou
- RecruitingBiomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06382103
Age not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingPhase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06389422
Age 18 years to 90 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingSintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397222
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingDEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06397235
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingCadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06406634
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- Phase
- Early phase 1
- Started
- 2024-10
- Registry
- NCT06418659
Age 18 years to Not stated (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingRecurrent Liver Cancer: Reconceptualization and Reevaluation
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06430983
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing
- RecruitingFruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06446154
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAdjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06454578
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingClinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06461624
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06467799
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPalliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06470256
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBackline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06478927
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingCheckpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06482801
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06485466
Age 18 years to 80 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingLenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06492395
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06492408
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAdjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06498622
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06515314
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingProspective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06519578
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06530251
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingAnti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06537908
Age 18 years to 90 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingStudy on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06542796
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEarly-stage Detection of Liver Cancer by Proteins in Peripheral Blood
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06544083
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAblation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06550921
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingTriple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561399
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou
- RecruitingOral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06563947
Age 18 years to 75 years (registered criteria)
Led by Shenzhen Third People's HospitalShenzhen
- RecruitingNeoadjuvant Triple Therapy for Resectable HCC
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06569498
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingPostoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06581315
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTriple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06602011
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingmFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06607107
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingThe Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingdTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609863
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDonafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06609876
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- Phase
- Phase 3
- Started
- 2024-10
- Registry
- NCT06618664
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingTIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06622031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCorrelation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06623474
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingHAIC Compared With TACE in Huge Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06641713
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06644430
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSingle-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
- Phase
- Phase 2/Phase 3
- Started
- 2024-11
- Registry
- NCT06644937
Age 18 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingClinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2024-11
- Registry
- NCT06652243
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06653062
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingMts105 for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06689540
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingIntravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06694636
Age 25 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingY-90 SIRT for Unresectable HCC Larger Than 7cm
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06707233
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06742424
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingThe Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06746194
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNovel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06849180
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingPlasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06864221
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
- Phase
- Phase 4
- Started
- 2024-12
- Registry
- NCT06930573
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07070362
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing
- RecruitingAn Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT07101237
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT07838415
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05475613
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05489289
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
- Phase
- N/A
- Started
- 2023-05
- Registry
- NCT05596630
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCamrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05613478
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPrevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
- Phase
- N/A
- Started
- 2023-02
- Registry
- NCT05738980
Age 18 years to 75 years (registered criteria)
Led by Beijing HospitalBeijing
- RecruitingAtezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05751343
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingDigitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT05870969
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPhase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05917431
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingLenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05920863
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingGPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2023-01
- Registry
- NCT05926726
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingLenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT05954897
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingSingle Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT05970666
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingTACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05984511
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingSintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-08
- Registry
- NCT05985798
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSIRT for Potentially Resectable HCC
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05994859
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPerioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06031285
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
- Phase
- Phase 3
- Started
- 2023-10
- Registry
- NCT06041477
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06060769
Age 18 years to Not stated (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingPrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06157060
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou
- RecruitingInfusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT06172205
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingHAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06187961
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingDEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06190665
Age 18 years to 80 years (registered criteria)
Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing
- RecruitingFOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06201065
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingApplication of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06219096
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingStudy on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2023-09
- Registry
- NCT06383520
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingImage Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT06559761
Age 18 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT06746701
Age 18 years to 65 years (registered criteria)
Led by Xiangya Hospital; 2 listed hospitals as study sitesChangsha, Guangzhou, Hengyang
- RecruitingProspective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT06788353
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingEfficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06904014
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05155189
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingStudy Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-02
- Registry
- NCT05323201
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingA Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2022-08
- Registry
- NCT05409482
Age 18 years to 75 years (registered criteria)
Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou
- RecruitingCT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
- Phase
- N/A
- Started
- 2022-05
- Registry
- NCT05433467
Age 18 years to Not stated (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- RecruitingMicrowave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05444478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingEfficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
- Phase
- N/A
- Started
- 2022-08
- Registry
- NCT05484908
Age 18 years to 65 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingLenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05608213
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingStudy of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT05620706
Age 40 years to 70 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
- RecruitingClinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
- Phase
- Not given
- Started
- 2022-12
- Registry
- NCT05661786
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingGoal-directed LCVP Based on HP in Laparoscopic Hepatectomy
- Phase
- N/A
- Started
- 2022-05
- Registry
- NCT05887661
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingEfficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT06870942
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingNeo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
- Phase
- N/A
- Started
- 2021-02
- Registry
- NCT04777942
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2021-01
- Registry
- NCT04803318
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingIntratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-03
- Registry
- NCT04952272
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai
- RecruitingThe Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
- Phase
- Early phase 1
- Started
- 2021-09
- Registry
- NCT05035108
Age 30 years to 80 years (registered criteria)
Led by Sir Run Run Shaw HospitalHangzhou
- RecruitingGPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2021-09
- Registry
- NCT05047510
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesLuzhou, Zhuhai
- RecruitingCryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2021-09
- Registry
- NCT05057845
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Phase
- Phase 2/Phase 3
- Started
- 2021-06
- Registry
- NCT05062837
Age 18 years to 75 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingAntiviral Therapy for Patients With Liver Cancer After Surgery
- Phase
- Not given
- Started
- 2021-12
- Registry
- NCT05466565
Age 18 years to 65 years (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingHAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2021-01
- Registry
- NCT06333561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRFA Plus Carrizumab vs Carrizumab Alone for HCC
- Phase
- Phase 2
- Started
- 2020-08
- Registry
- NCT04150744
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
- Phase
- Phase 2
- Started
- 2020-12
- Registry
- NCT04615143
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingIntra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Phase
- Phase 2
- Started
- 2020-11
- Registry
- NCT04770207
Age 18 years to 99 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAmbispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05520788
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCombined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05713994
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou
- RecruitingInfusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03949231
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTo Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2019-12
- Registry
- NCT04365751
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT07782632
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingThe Overall Survival of Patients With Unresectable HCC in Real-life
- Phase
- Not given
- Started
- 2018-07
- Registry
- NCT03612726
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingRegional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
- Phase
- Not given
- Started
- 2018-06
- Registry
- NCT06876753
Age 18 years to 80 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Phase
- Phase 1
- Started
- 2017-07
- Registry
- NCT03198546
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingCombination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2009-12
- Registry
- NCT02851784
Age not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingNK521 in the Treatment of Advanced Solid Tumors
- Phase
- Early phase 1
- Started
- 2027-01
- Registry
- NCT07657416
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- Not yet recruitingShuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
- Phase
- Phase 2
- Started
- 2027-09
- Registry
- NCT07691645
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingIntegration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- Phase
- Not given
- Started
- 2027-01
- Registry
- NCT07912853
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingFAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07314372
Age 18 years to Not stated (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- Not yet recruitingIvarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07324473
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing
- Not yet recruitingExploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328802
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07337031
Age 18 years to 75 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- Not yet recruitingHead to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07352345
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07356037
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- Not yet recruitingDrug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07363356
Age 18 years to 70 years (registered criteria)
Led by Eastern Hepatobiliary Surgery HospitalShanghai
- Not yet recruitingA Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07368023
Age 16 years to Not stated (registered criteria)
Led by Ningbo Medical Center Lihuili HospitalNingbo
- Not yet recruitingA Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07392866
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingSafety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07480382
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingSafety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07487402
Age 19 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingBenmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07537777
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingLocal Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07537946
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSurgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07537959
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingDenosumab Strategy for Liver Cancer With Bone Metastases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07537972
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingEfficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07553767
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNingbo
- Not yet recruitingEpalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07557914
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingPhase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07558200
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingNanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07565415
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingYMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07580261
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingHybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07582419
Age 18 years to 85 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07583316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingMultimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07596134
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou
- Not yet recruitingYttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07657273
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07682272
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of Combination Therapy in Patients With Resectable Liver Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07684040
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- Not yet recruitingA Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-11
- Registry
- NCT07691762
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07724951
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai
- Not yet recruitingAI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07729618
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingAI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07732504
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07749859
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEvaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07761286
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin
- Not yet recruitingPragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07768085
Age 18 years to Not stated (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- Not yet recruitingHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07780357
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingA Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
- Phase
- Phase 4
- Started
- 2026-08
- Registry
- NCT07790419
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07813572
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- Not yet recruitingJS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Registry
- NCT07823348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai
- Not yet recruitingHeterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07824765
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingTACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07836309
Age 16 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingFecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07847671
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingPhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07861425
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
- Not yet recruitingLenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07870772
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingSBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07882056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07919717
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingFOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Registry
- NCT06409637
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingLiver Cancer Prognosis Investigation Study
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06623734
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingCombination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06708650
Age 18 years to 75 years (registered criteria)
Led by Guiping People's Hospital
- Not yet recruitingSBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06739317
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingEffect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06749678
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06779461
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
- Not yet recruitingFusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06798194
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingQL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06822985
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06823050
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- Not yet recruitingIcaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT06896396
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingIcariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06900478
Age 18 years to 80 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingA Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06935175
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingRelationship Between FGF19 Overexpression and Disease Prognosis
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06938451
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07010588
Age 18 years to 75 years (registered criteria)
Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an
- Not yet recruitingHAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07045558
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingTauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07064668
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
- Not yet recruitingA Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07131501
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07156617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou
- Not yet recruitingGecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07157306
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingThe Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07180459
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHaikou
- Not yet recruitingEDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT07187284
Age 18 years to 75 years (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- Not yet recruitingAdebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07192848
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- Not yet recruitingA Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07239986
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07350070
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan
- Not yet recruitingPredictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07350824
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07352007
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Not yet recruitingPostoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06089369
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06196775
Age 18 years to 75 years (registered criteria)
Led by Harbin Medical University HospitalHarbin
- Not yet recruitingValue of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06317896
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06449846
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingCAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06641453
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAdjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
- Phase
- N/A
- Started
- 2023-03
- Registry
- NCT05602974
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingSBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
- Phase
- Phase 3
- Started
- 2023-03
- Registry
- NCT05718232
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingA Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Registry
- NCT05976568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingAdjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06041490
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Enrolling by invitationJS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT06882876
Age 18 years to 75 years (registered criteria)
Led by Xiangya HospitalChangsha
- Enrolling by invitationSurvival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07290764
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
- Enrolling by invitationA Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06647264
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Enrolling by invitationObservational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06712017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- Enrolling by invitationA Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Phase
- Phase 2
- Started
- 2021-12
- Registry
- NCT05441475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Enrolling by invitationThe Efficacy of Sequential RT After Triple Therapy for uHCC
- Phase
- Not given
- Started
- 2020-11
- Registry
- NCT07052448
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Primary liver cancer: diagnosis and treatment guideline (2026 edition)National Health Commission 国卫办医政函〔2026〕105号, 2026-04-09
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.